title: Optimizing viral and non-viral gene transfer methods for genetic modification of porcine mesenchymal stem cells.
abstract: BACKGROUND
  Mesenchymal stem cells (MSCs) provide an excellent source of pluripotent progenitor cells for tissue-engineering applications due to their proliferation capacity and differentiation potential. Genetic modification of MSCs with genes encoding tissue-specific growth factors and cytokines can induce and maintain lineage-specific differentiation. Due to anatomical and physiological similarities to humans, porcine research models have been proven valuable for the preclinical testing of tissue engineering protocols in large animals. The aim of this study was to evaluate optimized viral and non-viral ex vivo gene delivery systems with respect to gene transfer efficiency, maintenance of transgene expression, and safety issues using primary porcine MSCs as target cells.
  
  
  METHODS
  MSCs were purified from bone marrow aspirates from the proximal tibiae of four 3-month-old Danish landrace pigs by Ficoll step gradient separation and polystyrene adherence technique. Vectors expressing enhanced green fluorescent protein (eGFP) and human bone morphogenetic protein-2 (BMP-2) were transferred to the cells by different non-viral methods and by use of recombinant adeno-associated virus (rAAV)-mediated and retroviral gene delivery. Each method for gene delivery was optimized. Gene transfer efficiency was compared on the basis of eGFP expression as assessed by fluorescence microscopy and fluorescence-activated flow cytometry. BMP-2 gene expression and osteogenic differentiation were evaluated by realtime quantitative RT-PCR and histochemical detection of alkaline phosphatase activity, respectively.
  
  
  RESULTS
  Non-viral gene delivery methods resulted in transient eGFP expression by less than 2% of the cells. Using high titer rAAV-based vector up to 90% of the cells were transiently transduced. The efficiency of rAAV-mediated gene delivery was proportional to the rAAV vector titer applied. Retroviral gene delivery resulted in long-term transgene expression of porcine MSCs. A 26-fold increase in percentage of eGFP expressing cells (1.7%+/-0.2% versus 44.1% +/-5.0%, mean +/-SD) and a 68-fold increase in mean fluorescence intensity (327.4+/-56.6 versus 4.8+/-1.3) was observed by centrifugation of retroviral particles onto the target cell layer. Porcine MSCs that were BMP-2 transduced by optimized retroviral gene delivery demonstrated a significant increase in BMP-2 gene expression and showed increased osteogenic differentiation. Retrovirally transduced porcine MSCs were furthermore tested free of replication-competent viruses.
  
  
  CONCLUSIONS
  The non-viral gene transfer methods applied were significantly less efficient compared to the viral methods tested. However, due to advantages with respect to safety issues and ease of handling, improvement of non-viral gene delivery to primary MSCs deserves further attention. The high efficiency of rAAV-mediated gene delivery observed at high titers can be explained by the ability of rAAV vector to transduce nondividing cells and by its tropism towards porcine MSCs. rAAV-mediated gene delivery resulted in transient transgene expression due to lack of stable AAV genome integration. MLV-mediated retroviral gene delivery can be considered a safe method for long-term transgene expression by porcine MSCs, and is therefore particularly attractive for advanced tissue engineering strategies requiring extended transgene expression.
authors.affiliation: Orthopaedic Research Laboratory, Department of Orthopaedic Surgery E, Aarhus University Hospital, Aarhus, Denmark. maik.stiehler@ki.au.dk
authors.forename: Maik
authors.initials: M
authors.lastname: Stiehler
authors.forename: Mogens
authors.initials: M
authors.lastname: Duch
authors.forename: Tina
authors.initials: T
authors.lastname: Mygind
authors.forename: Haisheng
authors.initials: H
authors.lastname: Li
authors.forename: Michael
authors.initials: M
authors.lastname: Ulrich-Vinther
authors.forename: Charlotte
authors.initials: C
authors.lastname: Modin
authors.forename: Anette
authors.initials: A
authors.lastname: Baatrup
authors.forename: Martin
authors.initials: M
authors.lastname: Lind
authors.forename: Finn S
authors.initials: FS
authors.lastname: Pedersen
authors.forename: Cody E
authors.initials: CE
authors.lastname: Bünger
mesh_terms: D000818:Animals; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000235:genetics / Q000378:metabolism; D002460:Cell Line; D018014:Gene Transfer Techniques; D049452:Green Fluorescent Proteins / Q000378:metabolism; D006801:Humans; D009052:Leukemia Virus, Murine / Q000378:metabolism; D059630:Mesenchymal Stem Cells / Q000166:cytology*; D051379:Mice; D041681:NIH 3T3 Cells; D012190:Retroviridae / Q000378:metabolism; D013552:Swine; D013977:Tibia / Q000473:pathology; D023822:Tissue Engineering; D016212:Transforming Growth Factor beta / Q000235:genetics / Q000378:metabolism; D019076:Transgenes
chemical_list: C525718:BMP2 protein, human; C525719:Bmp2 protein, mouse; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D016212:Transforming Growth Factor beta; D049452:Green Fluorescent Proteins